XBiotech Inc
XBIT
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
88
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,996.90 | 37.80 | -0.42% |
| CAC 40 | 8,168.78 | 42.72 | -0.52% |
| DAX 40 | 24,897.40 | 28.71 | 0.12% |
| Dow JONES (US) | 48,977.18 | 594.79 | 1.23% |
| FTSE 100 | 10,058.25 | 53.68 | 0.54% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,395.82 | 160.19 | 0.69% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,663.58 | 76.35 | 0.56% |
| S&P 500 | 6,902.05 | 43.58 | 0.64% |
| S&P/ASX 200 | 8,682.80 | 45.80 | -0.52% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |